|
시장보고서
상품코드
2075383
아이 플루(결막염) 시장 : 질환 유형별, 투여 경로별, 약제 클래스별, 유통 채널별, 지역별Eye Flu (Conjunctivitis) Market, By Disease Type, By Route of Administration, By Drug Class, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
'아이 플루(결막염)' 시장은 2026년에 57억 2,000만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 99억 4,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 8.2%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 57억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 8.20% | 2033년 시장 규모 예측 : | 99억 4,000만 달러 |
'아이 플루'로도 알려진 결막염은 전 세계에서 수백만 명의 사람들이 앓고 있는 흔한 안과 감염증입니다. 이 질환은 눈의 흰자위를 덮고 눈꺼풀 안쪽을 감싸고 있는 얇고 투명한 막인 결막의 염증을 특징으로 합니다. 이러한 증상은 바이러스나 세균에 의한 감염, 알레르기, 자극 물질 등 다양한 원인에 의해 발생할 수 있습니다.
전 세계 아이 플루(결막염) 시장은 경쟁이 치열하며, 몇몇 주요 기업이 업계를 주도하고 있습니다. 노바티스 AG, 알라간, 바우슈 헬스, 산텐 제약, 존슨앤드존슨, 알렘빅 파마슈티컬스 등이 이 시장을 선도하는 기업 중 일부입니다. 이 기업은 안약, 연고, 경구약 등 아이 플루에 대한 다양한 제품과 치료법을 제공하고 있습니다.
시장 역학 :
세계의 '아이 플루'(결막염) 시장의 성장은 안구 감염증 유병률 증가, 눈 건강에 대한 의식의 향상, 의료 기술의 발전 등 여러 요인에 의해 주도되고 있습니다. 고령 인구 증가와 알레르기 및 자극 물질로 인한 발병률 상승도 시장 성장에 기여하고 있습니다.
그러나 전 세계 아이 플루(결막염) 시장의 성장을 저해할 가능성이 있는 몇 가지 제약 요인도 존재합니다. 여기에는 높은 치료비, 개발도상 지역의 의료 시설 이용 제한, 그리고 대체 치료법의 존재 등이 포함됩니다. 또한 시장은 엄격한 규제 요건이나 특정 약물에 수반되는 부작용 위험과 같은 과제에도 직면해 있습니다.
이러한 과제가 있음에도 불구하고 전 세계 아이 플루(결막염) 시장에는 수많은 성장 기회가 존재합니다. 효과적이고 안전한 치료법에 대한 수요 증가, 혁신적인 제품 개발, 그리고 신흥 경제국에서의 의료 인프라 확충이 가까운 미래에 시장 성장을 촉진할 것으로 예상됩니다.
본 조사의 주요 특징 :
- 이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 세계의 아이 플루(결막염) 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 아이 플루(결막염) 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 '아이 플루'(결막염)
제5장 세계의 아이 플루(결막염) 시장 : 질환 유형별, 2021-2033년
제6장 세계의 아이 플루(결막염) 시장 : 투여 경로별, 2021-2033년
제7장 세계의 아이 플루(결막염) 시장 : 약제 클래스별, 2021-2033년
제8장 세계의 아이 플루(결막염) 시장 : 유통 채널별, 2021-2033년
제9장 세계의 아이 플루(결막염) 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 섹션
KSA 26.07.08Eye Flu (Conjunctivitis) Market is estimated to be valued at USD 5.72 Bn in 2026 and is expected to reach USD 9.94 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.20% | 2033 Value Projection: | USD 9.94 Bn |
Eye flu, also known as conjunctivitis, is a common eye infection that affects millions of people worldwide. It is characterized by inflammation of the conjunctiva, the thin, transparent layer that covers the white part of the eye and lines the inner surface of the eyelids. This condition can be caused by various factors including viral or bacterial infections, allergies, or irritants.
Global eye flu (conjunctivitis) market is highly competitive, with several key players dominating the industry. Novartis AG, Allergan, Bausch Health, Santen Pharmaceutical, Johnson & Johnson, and Alembic Pharmaceuticals are some of the leading companies in this market. These companies offer a wide range of products and treatments for eye flu including eye drops, ointments, and oral medications.
Market Dynamics:
Global eye flu (conjunctivitis) market growth is driven by several factors including the increasing prevalence of eye infections, growing awareness about eye health, and advancements in medical technology. Rising geriatric population and increasing incidence of allergies and irritants also contributes to the market growth.
However, there are certain restraints that may hinder growth of the global eye flu (conjunctivitis) market. These include the high cost of treatment, limited access to healthcare facilities in developing regions, and the availability of alternative treatments. The market faces challenges such as stringent regulatory requirements and the risk of adverse effects associated with certain medications.
Despite these challenges, the global eye flu (conjunctivitis) market presents numerous opportunities for growth. Increasing demand for effective and safe treatments, the development of innovative products, and the expansion of healthcare infrastructure in emerging economies are expected to drive the market growth in the near future.
Key Features of the Study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- Key companies covered as a part of this study include Novartis AG, Allergan, Bausch Health, Santen Pharmaceutical, Johnson & Johnson, Alembic Pharmaceuticals, Akorn Pharmaceuticals, Alcon, Pfizer, Valeant Pharmaceuticals, Merck & Co., Similasan Corporation, Sun Pharmaceutical Industries, Prestige Consumer Healthcare, Lupin Pharmaceuticals, Alembic Pharmaceuticals, Aurolab, Intas Pharmaceuticals, Sun Pharma, and Cipla
- Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global eye flu (conjunctivitis) market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global eye flu (conjunctivitis) market
Detailed Segmentation:
- By Disease Type (Revenue, USD Bn, 2021 - 2033)
- Viral Conjunctivitis
- Bacterial Conjunctivitis
- Allergic Conjunctivitis
- Chemical Conjunctivitis
- Others
- By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Topical
- Oral
- Intravenous
- By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Antibiotics
- Anti-allergy
- Anti-inflammatories
- Combination
- Others
- By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Novartis AG
- Allergan
- Bausch Health
- Santen Pharmaceutical
- Johnson & Johnson
- Alembic Pharmaceuticals
- Akorn Pharmaceuticals
- Alcon
- Pfizer
- Valeant Pharmaceuticals
- Merck & Co.
- Similasan Corporation
- Sun Pharmaceutical Industries
- Prestige Consumer Healthcare
- Lupin Pharmaceuticals
- Alembic Pharmaceuticals
- Aurolab
- Intas Pharmaceuticals
- Sun Pharma
- Cipla
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER€(TM)s Analysis
- Merger and Acquisition Scenario
4. Global Eye Flu (Conjunctivitis)
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Eye Flu (Conjunctivitis) Market, By Disease Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Viral Conjunctivitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Bacterial Conjunctivitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Allergic Conjunctivitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Chemical Conjunctivitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
6. Global Eye Flu (Conjunctivitis) Market, By Route of Administration, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€" 2033
- Segment Trends
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
7. Global Eye Flu (Conjunctivitis) Market, By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€" 2033
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Anti-allergy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Anti-inflammatories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Combination
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
8. Global Eye Flu (Conjunctivitis) Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€" 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
9. Global Eye Flu (Conjunctivitis) Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022€"2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bausch Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Santen Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Akorn Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alcon
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Valeant Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Similasan Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Prestige Consumer Healthcare
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aurolab
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Intas Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
